Fluorine F 18 Choline

Phase 2Small molecule

UUniversity of California, San Francisco

Fluorine F 18 Choline is one of 63 small molecule programs targeting Prostate Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

HypoxiaActive, not recruiting

Prostate CancerPhase 2

Active, not recruiting

HypoxiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Preclinical

5 2

Trexall

Alnylam Pharmaceuticals

Preclinical

—3

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 4

Fluorine F 18 Choline

UUniversity of California, San Francisco

Phase 2

1 5

Duragesic

CCephalon

Preclinical

1 6

Triptorelin Pamoate

Ipsen

Preclinical

2 7

Osmitrol

BB. Braun Medical Inc.

Preclinical

—8

Ifex

BBaxter Healthcare Corporation

Preclinical

—9

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

—10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

11C- and 18F-Choline PET/MR Imaging for Prostate Cancer

Completed·UUniversity of California, San Francisco·Phase 2·NCT02397408·18 enrolled

Hypoxia1 trial

Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy

Completed·UUniversity of California, San Francisco··NCT04409314·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Fluorine F 18 Choline. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fluorine F 18 Choline compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fluorine F 18 Choline. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, San Francisco company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of California, San Francisco

Fluorine F 18 Choline

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prostate Cancer1 trial

Hypoxia1 trial

References

Drug Info

Quick Facts

Related News